InnoCare’s Oral Psoriasis Drug ICP‑488 Hits Phase III Target, Paving Path to Regulatory FilingTip Ranks·2 days ago, 04:37 AM09969-0.78%688428+0.70%
InnoCare says Phase II vitiligo trial of TYK2 inhibitor soficitinib meets primary endpoint at Week 24PUBT·Jul 16 at 03:51 AM09969-0.78%688428+0.70%
InnoCare’s TYK2 Inhibitor Soficitinib Hits Phase III Goal in Atopic DermatitisTip Ranks·Jul 15 at 06:07 AM688428+0.70%09969-0.78%
InnoCare Announces Publication in STTT (IF=81.2) of Phase 3 Results Showing Orelabrutinib Significantly Prolonged Progression-Free Survival in Treatment-Naïve CLL/SLLUnusual Whales·Jul 14 at 06:25 AM09969-0.78%688428+0.70%
InnoCare Announces First Patient Dosed in Clinical Trial of Novel CDH17 targeted ADC ICP-B208 in ChinaGlobeNewswire·Jul 5 at 08:00 PM09969-0.78%688428+0.70%
InnoCare Pharma hits 52-week low, falls 2% in Hong Kong tradingHK Stock Market Update·Jun 15 at 09:09 PM09969-0.78%688428+0.70%
InnoCare Presents Positive Phase 2b Data For Orelabrutinib In Treating Lupusnasdaq·Jun 5 at 10:10 AM09969-0.78%688428+0.70%
Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULARGlobeNewswire·Jun 4 at 11:06 PM688428+0.70%09969-0.78%
STOCKS | Hong Kong Semiconductor Stocks See Short-Term GainsCoinLive·Jun 3 at 09:09 PM688428+0.70%09969-0.78%
ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML ReleasedGlobeNewswire·Jun 2 at 09:47 PM09969-0.78%688428+0.70%
M Stanley Ratings and TPs on China Biotech StocksAASTOCKS News·May 29 at 02:32 AM688428+0.70%09969-0.78%
InnoCare Announces the Acceptance of New Drug Application for Orelabrutinib in Primary Immune Thrombocytopenia in ChinaUnusual Whales·May 28 at 04:24 AM09969-0.78%688428+0.70%
